Drug Profile
Terguride
Alternative Names: Dironyl; Dironyl maleate; Mysalfon; SH 406; Teluron; Transdihydrolisuride; VUFB 6638; ZK 31224Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Developer Bayer Schering Pharma; Bayer Yakuhin; ErgoNex Pharma; IVAX Pharmaceuticals s.r.o.; Pfizer
- Class Antiparkinsonians; Antipsychotics; Ergolines; Neuroprotectants; Small molecules; Urea compounds
- Mechanism of Action Dopamine D2 receptor agonists; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperprolactinaemia
- Discontinued Fibromyalgia; Fibrosis; Parkinson's disease; Pulmonary arterial hypertension; Schizophrenia
Most Recent Events
- 11 Aug 2011 Discontinued - Phase-II for Pulmonary hypertension in Germany (unspecified route)
- 11 Aug 2011 Discontinued - Phase-II for Pulmonary hypertension in Netherlands (unspecified route)
- 11 Aug 2011 Discontinued - Phase-II for Pulmonary hypertension in Poland (unspecified route)